JP2023539247A5 - - Google Patents
Info
- Publication number
- JP2023539247A5 JP2023539247A5 JP2023513299A JP2023513299A JP2023539247A5 JP 2023539247 A5 JP2023539247 A5 JP 2023539247A5 JP 2023513299 A JP2023513299 A JP 2023513299A JP 2023513299 A JP2023513299 A JP 2023513299A JP 2023539247 A5 JP2023539247 A5 JP 2023539247A5
- Authority
- JP
- Japan
- Prior art keywords
- feline
- seq
- fusion protein
- sequence
- vector according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069492P | 2020-08-24 | 2020-08-24 | |
| US63/069,492 | 2020-08-24 | ||
| PCT/US2021/047403 WO2022046809A1 (en) | 2020-08-24 | 2021-08-24 | Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539247A JP2023539247A (ja) | 2023-09-13 |
| JP2023539247A5 true JP2023539247A5 (enExample) | 2024-09-02 |
Family
ID=80355670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513299A Pending JP2023539247A (ja) | 2020-08-24 | 2021-08-24 | Ｇｌｐ－１受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230405150A1 (enExample) |
| EP (1) | EP4199942A4 (enExample) |
| JP (1) | JP2023539247A (enExample) |
| KR (1) | KR20230054419A (enExample) |
| CN (1) | CN116390745A (enExample) |
| AU (1) | AU2021332232A1 (enExample) |
| CA (1) | CA3190396A1 (enExample) |
| WO (1) | WO2022046809A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026039340A1 (en) | 2024-08-12 | 2026-02-19 | Akston Biosciences Corporation | Fc fusion protein therapeutics for companion animal obesity and methods of use |
| WO2026039341A1 (en) | 2024-08-12 | 2026-02-19 | Akston Biosciences Corporation | Fc fusion protein therapeutics for companion animal obesity and methods of use |
| WO2026039359A1 (en) | 2024-08-12 | 2026-02-19 | Akston Biosciences Corporation | Fc fusion protein therapeutics for companion animal obesity and methods of use |
| CN120005002B (zh) * | 2025-04-22 | 2025-07-25 | 西宝生物科技（上海）股份有限公司 | 一种glp-1类似物的生物发酵制备方法及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL155812A0 (en) * | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| US9511103B2 (en) * | 2011-04-20 | 2016-12-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity |
| WO2017024198A1 (en) * | 2015-08-06 | 2017-02-09 | The Trustees Of The University Of Pennsylvania | Glp-1 and use thereof in compositions for treating metabolic diseases |
| EP3481413A4 (en) * | 2016-07-08 | 2020-01-08 | Askgene Pharma, Inc. | FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US12297272B2 (en) * | 2017-08-15 | 2025-05-13 | Eianco US inc. | IgG Fc variants for veterinary use |
| CN120904316A (zh) * | 2018-12-27 | 2025-11-07 | 伊兰科美国公司 | 兽用IgG Fc变体 |
-
2021
- 2021-08-24 CA CA3190396A patent/CA3190396A1/en active Pending
- 2021-08-24 WO PCT/US2021/047403 patent/WO2022046809A1/en not_active Ceased
- 2021-08-24 EP EP21862600.0A patent/EP4199942A4/en active Pending
- 2021-08-24 KR KR1020237009389A patent/KR20230054419A/ko active Pending
- 2021-08-24 CN CN202180072448.2A patent/CN116390745A/zh active Pending
- 2021-08-24 JP JP2023513299A patent/JP2023539247A/ja active Pending
- 2021-08-24 US US18/042,729 patent/US20230405150A1/en active Pending
- 2021-08-24 AU AU2021332232A patent/AU2021332232A1/en active Pending